|2.||Renal Cell Carcinoma (Grawitz Tumor)
|3.||Neoplasm Metastasis (Metastasis)
|4.||Prostatic Neoplasms (Prostate Cancer)
|5.||Urinary Bladder Neoplasms (Bladder Cancer)
|1.||Linehan, W Marston: 48 articles (10/2015 - 01/2002)|
|2.||Escudier, Bernard: 20 articles (09/2015 - 04/2002)|
|3.||Schmidt, Laura S: 18 articles (03/2015 - 08/2002)|
|4.||Kwon, Taeg Kyu: 18 articles (04/2014 - 11/2005)|
|5.||Asano, Tomohiko: 18 articles (01/2014 - 08/2002)|
|6.||Asano, Takako: 17 articles (01/2014 - 08/2002)|
|7.||Dahiya, Rajvir: 16 articles (10/2014 - 09/2002)|
|8.||Stadler, Walter M: 15 articles (03/2014 - 01/2003)|
|9.||Selby, Peter J: 15 articles (11/2013 - 08/2003)|
|10.||Belldegrun, Arie S: 15 articles (05/2013 - 01/2003)|
|1.||sunitinib (Sutent)FDA Link
01/01/2010 - "The observed improvement in overall survival for patients treated with sunitinib further establishes this agent as the reference standard for first-line treatment of good-risk and intermediate-risk patients with metastatic renal cancer."
11/01/2015 - "Kidney cancer: Sunitinib: 2/1 is superior to 4/2."
01/01/2008 - "Sunitinib is widely used as first-line treatment for metastatic clear cell renal cancer (MCRC). "
01/01/2012 - "The STAR trial protocol: a randomised multi-stage phase II/III study of Sunitinib comparing temporary cessation with allowing continuation, at the time of maximal radiological response, in the first-line treatment of locally advanced/metastatic renal cancer."
01/01/2014 - "Sunitinib is the first-line treatment for renal cancer and we report a case of a man receiving this medication who also had diabetes. "
|2.||sorafenib (BAY 43-9006)FDA Link
03/01/2013 - "This study reveals that Sorafenib is effective in patients with hepatocarcinoma and renal cancer, essentially depending on the baseline clinical status of the patients. "
06/01/2015 - "These data indicate that combination therapy of sorafenib and anti-CTLA-4 Ab may be effective in advanced kidney cancer patients."
06/25/2013 - "As a safe and effective agent for advanced kidney cancer, sorafenib is well-tolerated in patients. "
08/01/2009 - "Safety and efficacy of sorafenib therapy in patients with metastatic kidney cancer with impaired renal function."
11/01/2013 - "We examined the predictive value of CAIX in estimating treatment outcome in patients receiving sorafenib vs. placebo as part of the Treatment Approaches in Renal Cancer Global Evaluation Trial (TARGET) study. "
06/30/1993 - "Recently, the subcutaneous administration of low-dose IL-2 was found to be a well-tolerated and effective treatment for renal cancer. "
01/01/1992 - "This study was performed to investigate the efficacy of IL-2 subcutaneous therapy alone in advanced renal cancer patients pretreated with interferon-2 alpha. "
01/01/2011 - "We present here a case series of 72 patients with metastatic renal cancer given first-line treatment with HD IL-2. "
04/01/1988 - "To confirm the antitumor efficacy of treatment with interleukin-2 and lymphokine-activated killer cells in patients with metastatic renal cancer. "
09/15/2008 - "Randomized study of intravenous versus subcutaneous interleukin-2, and IFNalpha in patients with good prognosis metastatic renal cancer."
02/01/2009 - "A prominent member in its class of medications, temsirolimus has already been shown to improve overall survival in advanced kidney cancer, when compared with the previous standard, IFN-alpha. "
01/01/2015 - "The aim of this study was to investigate the outcomes of an unselected group of patients with renal cancer treated with temsirolimus in a compassionate use program. "
08/01/2014 - "Temsirolimus in daily use: results of a prospective multicentre noninterventional study of patients with metastatic kidney cancer."
06/01/2014 - "The procedure is applied to analyze the aforementioned renal cancer study and identify gene transcripts and possible time-interactions that are relevant to CCI-779 metabolism in peripheral blood."
06/15/2004 - "Based on our results, weekly doses of 25, 75, and 250 mg CCI-779 not based on classical definitions of maximum-tolerated dose are being tested in phase II trials in patients with breast and renal cancer."
|5.||Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)IBA
08/01/2013 - "The introduction of therapy targeting vascular endothelial growth factor (VEGF) and the mammalian target of rapomycin (mTOR) has significantly improved the outcome of patients with metastatic renal cancer. "
01/01/2015 - "Decreased efficacy of drugs targeting the vascular endothelial growth factor pathway by the epigenetic silencing of FLT1 in renal cancer cells."
07/01/2013 - "In the present study, renal cancer 786‑0 cell‑derived exosomes significantly promoted angiogenesis via upregulation of VEGF expression in HUVECs, which may be induced by the downregulation of hepaCAM."
07/15/2012 - "This study describes, for the first time, the angiostatic response in human primary renal cancers at the tissue level upon treatment with VEGF-targeted therapy. "
09/01/2011 - "In this study, we investigated the effects of Res on the expression of the vascular endothelial growth factor (VEGF) gene and on cell proliferation in human renal cancer (786-0) cells. "
|6.||Interferon-alpha (Interferon Alfa)FDA Link
06/01/2009 - "The doses of this regimen may be tolerable, and might be an available treatment option for interferon alpha-resistant advanced renal cancer."
06/01/2005 - "Interferon alpha for the treatment of advanced renal cancer."
10/04/2004 - "The systemic inflammatory response, performance status and survival in patients undergoing alpha-interferon treatment for advanced renal cancer."
08/01/2001 - "Differences in cell kinetic changes among renal cancer cell lines treated with interferon-alpha."
05/01/2001 - "The current status of interferon-alpha treatment in advanced renal cancer."
09/01/2012 - "The aim of this overview is to report the current role of bevacizumab in the treatment of metastatic kidney cancer and to highlight possible combinations or sequential strategies that involve other targeted agents."
12/01/2010 - "Here, we report a 48-year-old man with a history of metastatic renal cancer, who developed colonic perforation secondary to bevacizumab. "
02/01/2009 - "Bevacizumab in kidney cancer: new indication. "
07/01/2007 - "New challenges in kidney cancer therapy: bevacizumab."
09/15/2004 - "Bevacizumab for patients with metastatic renal cancer: an update."
12/01/2015 - "Retrospective analysis on safety and efficacy of everolimus in treatment of metastatic renal cancer patients receiving dialysis."
01/01/2010 - "Clinical trials are in progress to examine additional roles for everolimus in renal cancer, alone and in combination with other agents."
03/01/2014 - "[Experience with everolimus therapy for patients with metastatic renal cancer in Hungary]."
08/16/2013 - "Long lasting response to second-line everolimus in kidney cancer."
06/01/2012 - "Further developments for improving response and tolerance to irradiation for advanced renal cancer: concurrent (mTOR) inhibitor RAD001 and helical tomotherapy."
|9.||Protein-Tyrosine Kinases (Tyrosine Kinase)IBA
01/01/2006 - "Among the novel targeted agents, multiple tyrosine kinase inhibitors were proved to be clinically effective against advanced clear cell renal cancer, changing the standard of care. "
01/01/2010 - "Clinical trials are currently ongoing with agents targeting the tyrosine kinase domain of MET in sporadic and hereditary forms of papillary kidney cancer. "
09/01/2015 - "Emerging tyrosine kinase inhibitors for the treatment of renal cancer."
09/01/2012 - "Use of tyrosine kinase inhibitors in patients with metastatic kidney cancer receiving haemodialysis: a retrospective Italian survey."
10/01/2009 - "Effect of the UK postcode lottery on survival of patients with metastatic renal cancer: an audit of outcomes in patients with metastatic renal cancer suitable for treatment with tyrosine kinase inhibitors."
10/01/2006 - "For the past 15 years, immunoreactive cytokines have been the mainstay of treatment for metastatic renal cancer. "
09/01/2006 - "Cytokines have been the mainstay of treatment for metastatic renal cancer for the past 20 years. "
09/15/2004 - "Immunoreactive cytokines have been the mainstay of treatment of renal cancer for the past 15 years. "
04/01/2002 - "The authors report the experience of the investigators of the Groupe Français d'Immunotherapie in the treatment of metastatic renal cancer by cytokines based on several clinical trials conducted successively between 1991 and 1998. "
01/01/2008 - "Until some years ago, systemic therapy for kidney cancer consisted of cytokines. "
02/01/2005 - "Most patients who develop kidney cancer are effectively treated with a radical nephrectomy; however, for those patients who present with or develop metastatic disease, the therapeutic options are limited. "
03/01/2004 - "This is most apparent in kidney cancer, where laparoscopic radical nephrectomy is now considered to be a gold standard. "
02/01/2014 - "Our small but prospective study showed significant reduction in uKIM-1/uCr after nephrectomy in the KIM-1 positive group, suggesting that urine KIM-1 may serve as a surrogate biomarker for kidney cancer and a non-invasive pre-operative measure to evaluate the malignant potential of renal masses."
09/01/2011 - "Cytoreductive nephrectomy is considered beneficial in patients with metastasised kidney cancer but only a minority of these patients undergo cytoreductive surgery. "
09/01/2013 - "The cytoreductive nephrectomy as first-line treatment of locally advanced or metastatic kidney cancer is now controversial with the advent of new targeted anti-angiogenic therapies. "
01/01/1997 - "Complete remission of extensive metastatic renal cancer following immunotherapy."
04/01/2011 - "For years, immunotherapy was the mainstay of treatment for advanced kidney cancer. "
08/01/2006 - "In addition, understanding of the basic biology and genetics of kidney cancer has led to improved prognostication and the development of effective immunotherapies for advanced disease. "
05/01/1995 - "Several forms of immunotherapy are apparently effective in inducing clinical remissions in metastatic renal cancer, but their benefit on survival times have not been demonstrated so far. "
09/01/2015 - "In this nationwide study, we found changes in the pattern of health care costs for patients with metastatic kidney cancer after implementation of targeted therapy compared to an immunotherapy control period; however, total health care costs and income from employment were without significant changes."
|3.||Drug Therapy (Chemotherapy)
12/01/1991 - "We conclude that sarcomatoid renal cancer is highly malignant and chemotherapy-resistant, but radiation may be partially effective."
04/01/1993 - "A better understanding of the mechanisms of chemoresistance of renal cancer should lead, in the near future, to the use of drugs capable of increasing the efficacy of cytotoxic chemotherapy in this tumour. "
01/01/1997 - "These results indicate that PGP levels correlate with MDR levels and suggest that chemotherapy using chemosensitizers might be effective in the treatment of renal cancers with overexpression of PGP."
06/01/1991 - "Chemotherapy for the myeloma which was carried out before the operation for renal cancer was not only effective for control of the myeloma, but also decreased the pulmonary congestion and improved the heart function. "
02/01/1990 - "These results suggested that UFT chemotherapy for advanced renal cancer was clinically effective."
|4.||Heterologous Transplantation (Xenotransplantation)
01/01/2015 - "In the present study, we established unique primary xenograft models, KURC1 (Kyoto University Renal Cancer 1) and KURC2, from freshly isolated ccRCC specimens. "
12/01/2013 - "In contrast, in renal cancer xenografts, vascular effect evaluated by measuring endothelial cell apoptosis was related to mouse Vegfr1, Vegfr2 and Vegfa-164 expression. "
01/15/2013 - "We further show that human FLCN exhibited evolutionarily conserved function and that Rpt4 knockdown inhibits the growth of FLCN-deficient human renal cancer cells in mouse xenografts. "
01/01/2013 - "The isolation and characterization of renal cancer initiating cells from human Wilms' tumour xenografts unveils new therapeutic targets."
07/15/2012 - "Using a mouse xenograft model of kidney cancer, characterized by subcapsular implantation of Caki-1 clear cell human kidney cancer cells, we examined tissue, serum, and urine all obtained simultaneously at baseline (urine) and at, or close to, animal sacrifice (urine, tissue, and plasma). "
|5.||Lymph Node Excision (Lymph Node Dissection)
03/01/2014 - "Routine lymphadenectomy does not appear to yield benefit in kidney cancer but maybe helpful in those with grossly identifiable disease. "
01/01/1989 - "[Improved actuarial results in the treatment of kidney cancer by systematic lymph node excision]."
01/01/1983 - "[Can the long-term survival in cancer of the kidney in adults be improved by cellulo-lymphadenectomy?]."
02/01/2013 - "Lymph node excision for renal cancer."
08/01/2012 - "Kidney cancer: lymphadenectomy for RCC-how many nodes?"